According to the paper "Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation" published in Krager Journal in June 2021, overactive bladder is relatively frequent worldwide, with an overall prevalence of 11.8%. In Europe, the incidence of overactive bladder in persons over the age of 18 is 15.6% for men and 17.4% for women. According to the same source, the prevalence of overactive bladder was 5.9% in males and 6.0% in women in Asia. With such a high disease burden, the market segment is likely to develop.
Access Full Report @ https://www.databridgemarketresearch.com/es/reports/global-bladder-disorders-market
Data Bridge Market Research analyses that the Bladder Disorders Market will grow at a CAGR of 11.40% in the forecast period of 2022 to 2029 and is expected to reach USD 13,085.04 million by 2029 from USD 9,419.97 million in 2021. There is a growing awareness of cancer among both healthcare professionals and the general public. This is partly due to increased media coverage of cancer and educational initiatives from patient advocacy groups and other organizations. As cancer awareness grows, so does the demand for cancer testing. Significant technological advancements have been in the diagnosis and treatment of bladder disorders. These advancements have made it easier to diagnose bladder disorders and have also made it possible to offer more effective treatments for them.
Growing aging population base is expected to drive the market's growth rate
The global population is aging, and this is leading to an increase in the prevalence of bladder disorders. This is because bladder disorders are more common in older adults. For instance, the prevalence of overactive bladder (OAB) is estimated to be 16% in adults over the age of 65. There is a growing awareness of bladder disorders among the general public and healthcare professionals. This is leading to more people being diagnosed with bladder disorders, and it is also leading to more people seeking treatment for bladder disorders.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014- 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Zydus Group (India), Medtronic (Ireland), Urovant Sciences (U.S.), Astellas Pharma Inc. (Japan), Sun Pharmaceutical Industries Ltd. (India), Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Viatris Inc. (U.S.), Laborie (U.S.), Boston Scientific Corporation (U.S.), Axonics, Inc. (u.S.), Merck & Co., Inc. (U.S.), Blue Wind Medical (Israel), Valencia Technologies (U.S.), Gaylord Chemical Company, L.L.C. (U.S.), Coloplast Corp (Denmark), Swati Spentose (India)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The bladder disorder market is segmented on the basis of type, treatment type, end user and distribution channel.
- On the basis of type, global bladder disorders market is segmented into cystitis, urinary incontinence, overactive bladder, interstitial cystitis, bladder cancer.
Overactive bladder segment of type segment is anticipated to dominate the bladder disorder market
The overactive bladder segment is expected to dominate the global bladder disorders market with 36.64% market share due to growing number of patients with overactive bladder. Rising geriatric population and growing incidence of diseases, such as Parkinson's disease, leads to overactive bladder disorder,
- On the basis of treatment type, global bladder disorders market is segmented into surgery, medication and non-surgical.
Medication segment is projected to hold the largest share of treatment segment in the bladder disorder market
The medication segment is expected to dominate the global bladder disorders market with 69.46% market share because it relaxes the muscle of bladder and can increase the holding capacity of the bladder. It might also increase the amount which able to urinate at one time. This may aid to empty the bladder more completely.
- On the basis of end user, global bladder disorders market is segmented into hospitals, clinics, ambulatory surgery centers and others. Hospitals segment is expected to dominate the global bladder disorders market with 49.26 % market share owing to the growing healthcare infrastructure development.
- On the basis of distribution channel, global bladder disorders market is segmented into direct sales, retail sales. Direct sales segment is expected to dominate the global bladder disorders market with 58.47% market share owing to the growth and expansion of distribution channels.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players: Invitae Corporation (U.S.), PerkinElmer Inc (U.S.), Quest Diagnostics Incorporated (U.S.), Ravgen (U.S.), GeneDx, LLC (U.S.), Illumina, Inc. (U.S.), Natera, Inc. (U.S.), Centogene N.V. (Germany)., 4baseCare (India), Biocartis (Belgium), Fulgent Genetics (U.S.), BioReference Health, LLC (U.S.), LifeLabs (U.S.), Abbott (U.S.), BIO-HELIX (Taiwan), Eurofins Scientific (Luxembourg).
Market Development
- In 2022, Dr. Reddy's Laboratories introduced fesoterodine fumarate extended-release tablets, a therapeutic generic equivalent to Pfizer's Toviaz (fesoterodine fumarate) ER tablets in the United States for the treatment of overactive bladder (OAB). Fesoterodine fumarate is an anticholinergic medication that works by relaxing the bladder muscles, which helps reduce the frequency of urination and urgency. Dr. Reddy's Laboratories' generic version of Toviaz is expected to be a more affordable option for patients with OAB.
- In 2021, Medtronic plc received approval from the United States Food and Drug Administration (FDA) to proceed with an investigational device exemption (IDE) trial to evaluate its internally developed implantable tibial neuromodulation (TNM) device. TNM is a minimally invasive procedure that involves implanting a small device in the leg that sends electrical impulses to the tibial nerve. These impulses help to relax the muscles in the bladder, which can help to reduce the frequency of urination and urgency. The IDE trial is a first step towards FDA approval of TNM for the treatment of OAB.
- In 2022, Valencia Technologies Corporation received United States Food and Drug Administration (FDA) premarket approval (PMA) of its eCoin leadless tibial neurostimulator for the treatment of urinary urge incontinence (UUI). eCoin is a small, wireless device that is implanted in the leg to deliver electrical impulses to the tibial nerve. These impulses help to relax the muscles in the bladder, which can help to reduce the frequency of urination and urgency. eCoin is the first leadless TNM device to receive FDA approval for the treatment of UUI.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the bladder disorders market during the forecast period 2022-2029
North America is the largest market for bladder disorders. The United States is the largest market in North America, followed by Canada. This is due to the high prevalence of cancer, well-established healthcare infrastructure, and increased awareness of bladder disorders.
Asia-Pacific is estimated to be the fastest-growing region in the bladder disorders market in the forecast period 2022-2029
Asia-Pacific is expected to grow at the fastest rate of all the regions as the region is experiencing rapid economic growth, which is leading to an increase in healthcare spending. This is creating opportunities for the growth of the market in Asia-Pacific. China, India, and Japan are the largest markets in Asia-Pacific.
For more detailed information about the bladder disorders market report, click here – https://www.databridgemarketresearch.com/es/reports/global-bladder-disorders-market
